logo
Reversing Inaccurate Penicillin Allergy Labeling

Reversing Inaccurate Penicillin Allergy Labeling

Medscape12-05-2025
Accurate labeling of penicillin allergies is essential, but unconfirmed penicillin allergies may have negative effects on individual and public health, according to experts.
A trend toward 'de-labeling' by testing individuals with documented penicillin allergies is gaining steam, in part as a way to reduce antibiotic use and curb the emergence of more resistant bacteria, according to Upeka Samarakoon, PhD, of Massachusetts General Hospital, Boston, and colleagues in a review article published in 2023 in the Annals of Allergy, Asthma, and Immunology . The article outlined the benefits of de-labeling and identified how patients are labeled with a penicillin allergy.
Individuals acquire a penicillin allergy label either by reporting a past reaction to penicillin or displaying a reaction recorded by a healthcare provider. Removing the allergy label from a patient's medical record may involve an evaluation of reaction history and often following an in-office drug challenge, according to the authors.
Why Lose the Label?
Penicillin antibiotics are first-line treatments for infections commonly treated in primary care settings — strep throat, ear infections, and urinary tract infections, said Kimberly G. Blumenthal, MD, the corresponding author of the review article, in an interview.
'Inaccurate penicillin allergy labels lead to inferior clinical outcomes from using second- line treatments, which are often broad-spectrum antibiotics,' said Blumenthal, an allergist/immunologist and clinical researcher at Massachusetts General Hospital and associate professor of medicine at Harvard Medical School, Boston. 'Patients with unconfirmed penicillin allergy labels have an increased risk of treatment failures, healthcare-associated infections, and colonization or infection with resistant organisms,' she added.
Proactively de-labeling patients with unverified penicillin allergies will improve their future care as they will be able to receive first-line treatments in times of need, said Blumenthal.
'Awareness of the importance of penicillin allergy de-labeling does seem to be increasing in primary care, but barriers exist for implementing de-labeling practices outside of allergy specialist clinics,' Blumenthal told Medscape Medical News . More work is needed to increase penicillin allergy de-labeling by generalists, potentially through the use of electronic health records or other decision tools and algorithms to assess patients, she said.
Barriers to increased de-labeling in primary care include limited time, productivity targets, and pressure to achieve quality metrics for chronic health diseases, Blumenthal said. 'Additionally, primary care physicians report that they lack allergy knowledge and lack the resources needed for penicillin allergy evaluations,' she said. 'Potential solutions to these barriers include having a dedicated penicillin allergy de-labeling clinic, including questions on penicillin allergies during annual visits, and increasing education related to penicillin allergy de-labeling for generalists,' Blumenthal noted.
Clinician's Guide to De-Labeling
The use of simple allergy history tools can go a long way toward de-labeling a penicillin allergy, Blumenthal told Medscape Medical News . 'Many penicillin allergy labels lack a reaction or should not be there at all and warrant de-labeling based on history alone,' she said. For example, a patient who has subsequently taken penicillin with no reaction or had only a family history of penicillin allergy is a candidate for de-labeling, she said.
For individuals who may have an allergy, risk stratification tools such as PEN-FAST can identify low-risk patients who are suitable for de-labeling in primary care, Blumenthal said. 'A patient with a PEN-FAST score of 0, in my opinion, would be appropriate for primary care de-labeling in the US. Higher-risk patients can be referred to allergy specialists,' she added.
The 2023 article contains a more detailed explanation of the de-labeling process, which can be done in a few hours' time and at relatively low cost, according to the authors.
Safely Ruling Out the Allergy
The majority of patients who are labeled as allergic to penicillin are, in fact, not allergic, said John Kelso, MD, in a presentation on allergies at the annual meeting of the American College of Physicians (ACP), previously reported by Medscape Medical News . Patients labeled as penicillin-allergic but who have no history of severe cutaneous adverse reactions are candidates for de-labeling, Kelso said.
'Many patients go through their entire lives unable to receive the best treatment for infections because they are mislabeled as being allergic to penicillin,' he emphasized.
An intradermal skin test can confirm or rule out a penicillin allergy for patients who experienced hives after a first dose of a new course of penicillin, but blood tests are not reliable, Kelso said in his ACP presentation.
De-labeling has increased dramatically in the last few years, both in allergist offices and in primary care settings, driven in part by campaigns from the American Academy of Allergy, Asthma, and Immunology; American College of Allergy, Asthma, and Immunology; the Centers for Disease Control and Prevention; and the Infectious Diseases Society of America, Kelso told Medscape Medical News .
Clinicians often assume that the process of de-labeling a penicillin allergy is 'complicated, time-consuming, and dangerous,' but that is not the case, Kelso said.
To begin the de-labeling process, screen patients with appropriate questions to exclude those whose prior reaction may have been immediate anaphylaxis or a late-onset severe cutaneous adverse reaction, Kelso said in an interview. Once such patients are excluded, the process simply involves administration of a dose of amoxicillin followed by a 1-hour observation period in the clinic and asking the patients to report any late onset reactions that might develop over the next day or two, he said.
A large body of research exists to support de-labeling of penicillin allergies, Kelso told Medscape Medical News . 'Perhaps the most important finding is that 95% of patients who are labeled as being allergic to penicillin are not, either because the original reaction was coincidental or the allergy has been lost over time; thus, the vast majority of patients who undergo an amoxicillin challenge for penicillin de-labeling will do so uneventfully,' he noted. 'Once an appropriate history has been taken to exclude the patients who may be at risk of a more severe reaction, the remainder should be offered the de-labeling by amoxicillin challenge so that in the future they can offered the most appropriate treatment,' he said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

As Buffett as it Gets: 7 Reasons Why Berkshire Hathaway Just Bought This Monster Health Insurance Stock
As Buffett as it Gets: 7 Reasons Why Berkshire Hathaway Just Bought This Monster Health Insurance Stock

Yahoo

time21 minutes ago

  • Yahoo

As Buffett as it Gets: 7 Reasons Why Berkshire Hathaway Just Bought This Monster Health Insurance Stock

Key Points Berkshire Hathaway recently initiated a position in UnitedHealth Group stock. Shares of UnitedHealth have plummeted by roughly 40% this year. Despite some turbulence, its business boasts several attributes that Buffett seeks. 10 stocks we like better than UnitedHealth Group › At the close of each calendar quarter, financial institutions managing over $100 million are required to file a Form 13F with the Securities and Exchange Commission (SEC). These disclosures detail the stocks that Wall Street's "smart money" has been buying and selling -- giving investors a rare window into where professional money managers see opportunity. Few names in the investing world command more attention than Warren Buffett, whose leadership at Berkshire Hathaway has transformed it into one of the most respected and consistently market-beating portfolios of the modern era. According to its most recent 13F filing, Berkshire recently initiated a position in (NYSE: UNH) during the second quarter. The move comes at a time when UnitedHealth stock has been under heavy selling pressure -- weighed down by a string of negative headlines that have driven the stock 40% lower as of Aug. 18. Let's unpack why Berkshire's bet on UnitedHealth aligns squarely with Buffett's investment philosophy, and explore whether now is a good time to follow the Oracle of Omaha's lead. 1. UnitedHealth fits squarely into one of Buffett's favorite industries One of Buffett's favorite sectors has long been financial services, especially insurance companies. Berkshire's portfolio includes insurance giants like GEICO and Chubb, underscoring his conviction in the industry. Health insurers share many of the underlying business characteristics that make insurance such an attractive industry to Buffett. They provide mission-critical services while also collecting billions in premiums up front, long before claims are paid out. This structure gives insurers a unique combination of financial stability and durability, qualities that Buffett prizes. 2. Buffett loves moats Some of Berkshire's largest holdings include Apple, American Express, Coca-Cola, Moody's, and Visa. While these companies span different industries, they share a common thread: massive brand equity that makes them difficult to dislodge. Buffett has always favored businesses with durable economic moats. In the health insurance space, the idea of a moat is reinforced by and industry dominated by just a few major players -- with UnitedHealth being the largest among them. Right now, however, UnitedHealth's brand moat shows some small cracks in the armor, creating what Buffett likely views as a rare opportunity to invest in an industry leader while sentiment remains sour. 3. Recurring insurance fees + brand equity = heaps of cash flow Recurring insurance premiums paired with strong brand equity translates into powerful unit economics -- notably in the form of consistent free cash flow generation. For UnitedHealth, its vertically integrated model -- spanning insurance, healthcare services, and data analytics -- enables the company to produce tens of billions in annual cash flow. This fits neatly into Buffett's preference of favoring businesses with steady, predictable cash flow. Despite some recent hiccups, management has signaled confidence that growth will resume by next year -- suggesting even stronger cash flow and profitability metrics could arrive sooner than many anticipate. 4. UnitedHealth Group literally pays you to own the stock One way UnitedHealth puts its excess cash to work is by paying -- and steadily growing -- its dividend payment. This is a feature that Buffett undoubtedly appreciates. Known for his unwavering patience, Buffett often holds on to core positions for years, if not decades. Over time, that discipline has transformed some of Berkshire's greatest growth bets into reliable income streams -- with dividends serving as a reward for simply staying the course, even during periods of pronounced volatility. 5. The company is buying back shares, and... Another way UnitedHealth is delivering value to shareholders is through consistent stock buybacks. Companies often buy back their own stock as a signal that management thinks shares are undervalued. To put this into perspective, it's worth examining what UnitedHealth insiders have doing with their own shares -- a telling indicator of how those closest to the business view its long-term potential. 6. ... so are insiders; what could this suggest? According to SEC filings, several insiders at UnitedHealth -- including CEO Stephen Hemsley -- have collectively purchased roughly $30 million of stock in recent months, right in the middle of the sell-off. When combined with the company's aggressive share buybacks, this insider activity sends a clear message: Management is confident in UnitedHealth's ability to engineer a turnaround and views the stock as a bargain right now. 7. UnitedHealth Group stock is dirt cheap The chart benchmarks UnitedHealth Group against a set of managed care and insurance peers based on the price-to-earnings (P/E) multiple. At just 13x earnings, UnitedHealth sits squarely in the middle of this cohort. On its own, that doesn't reveal much. But zooming out, the picture becomes more clear: After months of valuation compression, UnitedHealth stock is now trading near five-year lows. This suggests that investors are pricing UnitedHealth as a low-growth (or even no-growth), high-risk opportunity rather than the industry leader it truly is -- one that would typically command a premium. Against this backdrop, Buffett's move makes perfect sense. He likely sees glaring misalignment between perceived risk and actual risk -- most of which is already reflected in the price. UnitedHealth remains a fundamentally strong business that has undergone a historic valuation derate. In Buffett's eyes, that looks less like trouble and more like an opportunity. Put simply, buying UnitedHealth stock at this moment is classic Buffett value investing. For these reasons, I think now is a lucrative opportunity to follow the Oracle's lead and scoop up shares of UnitedHealth stock for a bargain, too. Should you buy stock in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,624!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,117!* Now, it's worth noting Stock Advisor's total average return is 1,052% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 American Express is an advertising partner of Motley Fool Money. Adam Spatacco has positions in Apple. The Motley Fool has positions in and recommends Apple, Berkshire Hathaway, Moody's, and Visa. The Motley Fool recommends CVS Health and UnitedHealth Group. The Motley Fool has a disclosure policy. As Buffett as it Gets: 7 Reasons Why Berkshire Hathaway Just Bought This Monster Health Insurance Stock was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Oscar Health (OSCR) Tumbles 8% on Lack of Catalysts
Oscar Health (OSCR) Tumbles 8% on Lack of Catalysts

Yahoo

time21 minutes ago

  • Yahoo

Oscar Health (OSCR) Tumbles 8% on Lack of Catalysts

We recently published . Oscar Health, Inc. (NYSE:OSCR) is one of Wednesday's worst performers. Oscar Health dropped its share prices by 8.18 percent on Wednesday to close at $15.27 apiece as investors unloaded positions amid the overall market pessimism while waiting for fresh catalysts to spark buying appetite. Last week, Oscar Health, Inc. (NYSE:OSCR) teamed up with Hy-Vee Health for the launch of a new employer-backed insurance product called 'Hy-Vee Health with Oscar' in Des Moines, Iowa. Valeri Potapova/ The product, which supports the individual coverage health reimbursement arrangements (ICHRA), allows individuals and employees to choose their preferred health insurance packages and have them paid by their employers. According to Oscar Health, Inc. (NYSE:OSCR), the plan is available to 400,000 employees in greater Des Moines through their employer on the individual marketplace starting Nov. 1, 2025, for coverage effective Jan. 1, 2026. 'We are shaping the future of healthcare for consumers and employers. Everyone deserves healthcare that is affordable, convenient, and simple. Our partnership reflects the innovation we are driving in the individual market to exceed expectations across the country,' said Oscar Health, Inc. (NYSE:OSCR) CEO Mark Bertolini. While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

I Tested Out the $349 Headband That Trains Your Brain for Better Sleep, and It Actually Works
I Tested Out the $349 Headband That Trains Your Brain for Better Sleep, and It Actually Works

CNET

time22 minutes ago

  • CNET

I Tested Out the $349 Headband That Trains Your Brain for Better Sleep, and It Actually Works

Cole Kan/CNET I love naps, particularly power naps. Power naps are the perfect way to get that much-needed rest to help you get through the rest of your day. So when I had the chance to take a nap for work purposes, it immediately caught my attention. The assignment was to test a headband that promises to help you sleep on demand, and I was excited to give it a go. This Elemind headband is sleek and comfortable. Coming in at $349 (and an optional subscription fee if you need to access your sleep data), it's not exactly cheap. But it does come loaded with tech, including EEG functionality to read your brainwaves, an AI for processing that brain activity, and audio output to produce sounds that induce sleep -- a low-pitch, rhythmic buzz you can also feel. The sensation isn't intrusive or distracting, but rather almost feels like a light massage. "It's basically noise-canceling those brain waves that keep you awake," Meredith Perry, co-founder of Elemind, tells me. There are plenty of Reddit threads because of the intrigue around this device. The discussion is around whether it actually works, with many folks recommending it, while some others being on the fence about this tech, stating that it may be too early to be a market-ready device. To find the answers, I set out to test it myself. I've been working in the sleep industry for years and I've seen and tested a variety of gadgets and products that claim to help you sleep better. Honestly, I understand the skepticism surrounding a product like this, because not many such devices live up to their promises. Naturally, I was very eager to see if the Elemind headband was among the hundreds that didn't work or if it was going to be the breakthrough the space needed. Here's what I found. Putting the Elemind to the test Nasha Addarich Martinez/CNET I arrived at The Crosby Street Hotel in New York for my nap. Perry greeted me at the entrance of the room and explained the technology behind Elemind and to showed me how to properly put on the headband and turn it on. She also showed me how the app works and the data I can access when wearing the headband. Then she left me to nap. I'll briefly describe what happened next because -- spoiler -- I fell asleep. I remember lying down and hearing a low buzz that resembled bone conduction. I could hear the buzzing, but I could also feel it. At first, the rhythm was fast-paced, but as I started to drift off I felt it getting slower. The next thing I knew, I was waking up to the sound of the room door opening. It was Perry with a big smile because she knew the headband had worked based on my half-opened eyes and the bewildered look on my face. The nap was pretty short. We set the headband to 25 minutes. This wasn't my typical nap. Instead of a deep sleep, I felt like I was in an alpha state -- like a light sleep where I was still aware of my surroundings. When I woke up, I felt exactly how I normally feel after a nap, which was a little groggy. That feeling lasted only a few minutes, and I continued my day with no side effects or grogginess. This is the first sleep tech device I've seen that targets brain waves and redirects them in real-time. Research affiliated with Elemind claims that 76% of the people who wore the headband fell asleep faster, and that was certainly the case for me. What the data says According to the data I received from my nap, which was reviewed by neuroscientists at Elemind, my alpha wave activity remained high during my nap, which indicates that while I was resting and in light sleep, I didn't go into a deep sleeping stage. I suspected that would be the case for a 25-minute nap, and that also aligns with my experience wearing the headband. (I was aware of my surroundings but in a light sleep, kind of like how you feel when you're about to wake up in the morning.) Elemind The image above, which Elemind refers to as a plot, is a polar histogram that shows the performance of the headband while tracking my alpha waves. On the left side, the plot shows the target onset phase and the distribution of all the stimuli (gray bars). The right side is a similar plot but for the target stimulus offset phase. More simply put, "the onset [is] the phase of the brainwave when each sound pulse starts and offset is the phase of the brainwave when each sound pulse ends," said Ryan Neely, VP of science and research at Elemind. All of this means that the headband was working as intended (more pulses at the beginning when my brainwave activity was high, then, less frequently when my target brainwave activity was reached (224 degrees). The data confirms what I felt during my nap -- that I had a light sleep nap. I certainly felt like I was resting and also felt I fell asleep pretty fast (what I felt was only about a few minutes). I'd say it was a pretty good power nap, especially since it was only 25 minutes long at 2 p.m. I'm curious to see if it'll induce me into a more deep sleep during the night when I'm in the comfort of my home. How does the Elemind work? The headband is designed to help users fall asleep by targeting their alpha wave activity with sound pulses. This is a core feature of the patented algorithm that was developed at MIT and built into each band. Perry explained that the headband uses noninvasive neuromodulation technology to track your EEG brain activity and deliver acoustic stimulation synced to your brain's natural rhythms, in actual time. Every night you wear the headband, it learns more and evolves with you through its AI capabilities, becoming more effective with time. The AI behind the headband, which Elemind refers to as Sleep Tailor, learns your unique brain activity and sleep patterns to improve your rest. It gathers your sleep data and analyzes it to generate stimulation patterns to offset your brain activity. The headband can be worn all night and is comfortable enough to wear in all sleeping positions. Users can use Elemind in any way that suits their needs. For example, you can wear the headband just to fall asleep and take it off during the night, or you can choose to put the headband on only if you wake up and need help falling back to sleep. You can also use Elemind to nap during the day. To experience all of the Elemind's features, it's recommended that you wear it all night. You'll be able to use it to help you fall asleep, with real-time sleep staging, which will result in a comprehensive sleep report post-session, and to fall back asleep faster if you wake up up earlier than intended. Soon, the Elemind will also have a deep sleep stimulation feature, which will amplify delta waves during slow-wave sleep. Is the Elemind comfortable? I found the Elemind headband to be comfortable. It's made of soft material and it's adjustable in the back so you can make it tighter or looser as you prefer it. It should be tight enough that it doesn't fall off, but not tight enough that it's uncomfortable to sleep with. I mostly napped on my back, so I didn't have any issues with it sliding off. I did briefly lay on my side and couldn't feel it shifting or bunching up. For accurate readings, you only need to ensure that the sensors are in contact with your forehead. If you have long hair, Perry recommends wrapping it around your neck and under the hair, then gently sliding it up to your forehead and behind your ears. Lai Umali/CNET Is the Elemind worth it? Whether the Elemind headband would be worth the $349 to you will depend on a few factors. You might like Elemind if: You travel often and struggle with jetlag. You find it difficult to fall sleep. You wake up frequently during the night and struggle to fall back asleep. Elemind might not be for you if: You find a subtle buzz on your forehead too distracting. You don't have issues falling asleep or staying asleep. Where can I buy the Elemind headband? You can order the Elemind on its website. The product is past the preorder stage and is now available for purchase. In addition to the $349 price for the device, there's an optional membership to access sleep tracking, scores and metrics. Without the membership, you can still access the headband's core features of falling asleep and falling back to sleep faster. You do get the first month free with the purchase of the headband. You can choose to pay the membership annually, which will run you about $7 a month, or to pay it in monthly installments of $13.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store